Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHG:688505) — Stock Price
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHG:688505) is currently trading at CN¥7.94 CNY, up 0.51% today. Over the past 52 weeks, shares have ranged between CN¥6.68 and CN¥10.68. This page tracks Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 688505 stock market capitalisation.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥685.80 Million | CN¥709.40 Million | CN¥850.73 Million | CN¥1.03 Billion | CN¥1.14 Billion |
| Cost of Revenue | CN¥69.31 Million | CN¥63.46 Million | CN¥74.08 Million | CN¥86.29 Million | CN¥81.02 Million |
| Gross Profit | CN¥685.80 Million | CN¥645.95 Million | CN¥776.66 Million | CN¥944.87 Million | CN¥1.06 Billion |
| Research & Development | CN¥358.00 Million | CN¥325.79 Million | CN¥243.76 Million | CN¥226.85 Million | CN¥224.39 Million |
| SG&A | CN¥280.17 Million | CN¥41.70 Million | CN¥42.86 Million | CN¥44.87 Million | CN¥60.56 Million |
| Total Operating Expenses | CN¥841.20 Million | CN¥643.55 Million | CN¥679.57 Million | CN¥811.60 Million | CN¥841.91 Million |
| Operating Income | CN¥-155.40 Million | CN¥2.39 Million | CN¥97.09 Million | CN¥133.27 Million | CN¥217.38 Million |
| EBITDA | CN¥-102.36 Million | CN¥59.61 Million | CN¥152.61 Million | CN¥206.81 Million | CN¥270.89 Million |
| EBIT | CN¥-155.85 Million | CN¥6.12 Million | CN¥100.72 Million | CN¥133.97 Million | CN¥217.11 Million |
| Interest Expense | CN¥662.89K | CN¥664.32K | CN¥3.19 Million | CN¥1.68 Million | CN¥1.19 Million |
| Income Before Tax | CN¥-155.85 Million | CN¥5.46 Million | CN¥97.53 Million | CN¥132.29 Million | CN¥215.92 Million |
| Income Tax Expense | CN¥1.59 Million | CN¥-33.98 Million | CN¥-10.92 Million | CN¥-4.98 Million | CN¥3.54 Million |
| Net Income | CN¥-157.44 Million | CN¥39.73 Million | CN¥108.63 Million | CN¥138.00 Million | CN¥213.30 Million |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥2.39 Billion | CN¥2.59 Billion | CN¥2.88 Billion | CN¥2.98 Billion | CN¥2.78 Billion |
| Total Current Assets | CN¥1.49 Billion | CN¥1.61 Billion | CN¥1.87 Billion | CN¥2.07 Billion | CN¥1.93 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | CN¥33.32 Million | — |
| Net Receivables | CN¥201.34 Million | CN¥472.45 Million | CN¥624.02 Million | CN¥685.13 Million | CN¥677.49 Million |
| Inventory | CN¥33.21 Million | CN¥47.27 Million | CN¥43.65 Million | CN¥40.53 Million | CN¥35.63 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | CN¥0.00 | CN¥0.00 | CN¥0.00 | CN¥0.00 | CN¥0.00 |
| Total Liabilities | CN¥273.93 Million | CN¥281.23 Million | CN¥518.12 Million | CN¥722.99 Million | CN¥591.58 Million |
| Total Current Liabilities | CN¥245.62 Million | CN¥250.95 Million | CN¥505.02 Million | CN¥673.34 Million | CN¥528.20 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | CN¥-1.04 Billion | CN¥-1.18 Billion | CN¥-1.16 Billion | CN¥-1.18 Billion |
| Total Stockholder Equity | CN¥2.12 Billion | CN¥2.30 Billion | CN¥2.36 Billion | CN¥2.26 Billion | CN¥2.19 Billion |
| Retained Earnings | CN¥676.22 Million | CN¥864.75 Million | CN¥918.31 Million | CN¥882.24 Million | CN¥816.28 Million |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥141.40 Million | CN¥-14.77 Million | CN¥71.02 Million | CN¥165.27 Million | CN¥268.90 Million |
| Capital Expenditures | CN¥32.37 Million | CN¥42.67 Million | CN¥98.97 Million | CN¥87.30 Million | CN¥120.12 Million |
| Free Cash Flow | CN¥109.03 Million | CN¥-57.44 Million | CN¥-27.95 Million | CN¥77.96 Million | CN¥148.78 Million |
| Investing Cash Flow | — | CN¥-23.88 Million | CN¥-45.38 Million | CN¥-96.75 Million | CN¥-355.67 Million |
| Financing Cash Flow | — | CN¥-101.27 Million | CN¥-118.98 Million | CN¥11.61 Million | CN¥-101.16 Million |
| Dividends Paid | CN¥31.10 Million | CN¥93.29 Million | CN¥76.15 Million | CN¥72.03 Million | CN¥52.15 Million |
| Stock-Based Compensation | — | CN¥0.00 | CN¥-1.84 Million | CN¥7.69 Million | CN¥64.97 Million |
| Depreciation | CN¥72.78 Million | CN¥82.22 Million | CN¥62.23 Million | CN¥80.97 Million | CN¥60.85 Million |
| Change in Cash | CN¥90.79 Million | CN¥-139.61 Million | CN¥-93.41 Million | CN¥80.42 Million | CN¥-188.01 Million |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 11, 2025 | — | — | — |
| Apr 28, 2025 | — | — | — |
| Mar 28, 2025 | — | — | — |
| Aug 10, 2023 | 0.06 | — | — |
| Apr 28, 2023 | 0.01 | — | — |
| Mar 27, 2023 | 0.10 | — | — |
| Oct 27, 2022 | 0.07 | — | — |
| Aug 25, 2022 | -0.04 | — | — |